China’s Long-Awaited Reimbursement Mechanism for Pharma Products

China’s reimbursement mechanism for innovative pharmaceutical products

China’s pharma market is second only to that of the US, but China’s environment is highly competitive in terms of pricing and reimbursement of pharmaceutical products. Recent changes to China’s reimbursement policies, including frequent updates to the National Reimbursed Drug List (NRDL) and the inclusion of 250+ innovative products in the NRDL, make it a lucrative destination for pharmaceutical companies. In this insight paper, we cover the following:

  • China’s governing bodies and reimbursement mechanisms and policies

Key Takeaways

  • The NRDL has been updated annually since 2017

Originally published at


Raghu Patale serves as Delivery Manager leading the Life Sciences Corporate Strategy Research and Consulting vertical. His responsibilities include thought leadership, setting up new client engagements, client management, and generating business insights. He has over 10 years of experience in conducting life science research as a competitive intelligence and strategy consultant. He has supported a wide spectrum of client engagements focusing on competitive intelligence, therapy area research, market opportunity assessments, M&A support and report writing in oncology and other therapy areas for US, EU5, and Asian geographies.

Prior to this, Raghu was a Group Manager, leading the Pharma Practice at Evalueserve. He holds a Master’s degree in Pharmaceutical Sciences from the National Institute of Pharmaceutical Education and Research (NIPER).

We write about financial industry trends, the impact of regulatory changes and opinions on industry inflection points.